Emerald Mutual Fund Advisers Trust Acquires Shares of 1,018 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 1,018 shares of the biotechnology company’s stock, valued at approximately $127,000.

Other institutional investors have also added to or reduced their stakes in the company. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the second quarter valued at $31,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the first quarter valued at $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics in the second quarter valued at $43,000. Finally, UMB Bank n.a. grew its holdings in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the company from $185.00 to $179.00 in a report on Thursday, August 8th. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Finally, Raymond James reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $123.29 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The business has a 50-day moving average price of $127.42 and a 200 day moving average price of $132.67. The company has a market capitalization of $11.76 billion, a P/E ratio of 273.98 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $75.69 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.27) earnings per share. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.